HER2 positivity in breast carcinoma: A comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization

Applied Immunohistochemistry and Molecular Morphology

Volumn 13, Issue 2, 2005, Pages 194-200

  Loring, Pequita ^a   Cummins, Robert ^a   O'Grady, Anthony ^a   Kay, Elaine W ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Chromogenic in situ hybridization; Fluorescence in situ hybridization; HER2; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ACCURACY; ARTICLE; BREAST CARCINOMA; CELL HETEROGENEITY; CHROMOGENIC IN SITU HYBRIDIZATION; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM; TECHNOLOGY; TISSUE MICROARRAY;

ANEUPLOIDY; BREAST NEOPLASMS; CARCINOMA; CHROMOGENIC COMPOUNDS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 19444369429     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pai.0000132189.01233.6d     Document Type: Article

References (26)

1. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182.
2. Pinder SE, Ellis IO. Recommendations for HER2 testing. Immunocytochem. 2003;2:6-9.
3. Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
4. McCormick SR, Lillemoe TJ, Beneke J, et al. HER2 Assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002;117:935-943.
5. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
6. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
7. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
8. Zujewski JO. "Build quality in": HER2 testing in the real world. J Nat Can Inst. 2002;94:788-789.
9. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet. 2002;3:137-144.
10. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;11:783-792.
12. O'Grady A, Flahavan CM, Kay EW, et al. HER-2 analysis in tissue microarrays of archival human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. Appl Immun Molecul Morphol. 2003;11:177-182.
13. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. JMD. 2003;5:155-159.
14. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-145.
15. Tanner M, Gancberg D, Di Leo BA, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
16. Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657-665.
17. Park K, Kim J, Lim S, et al. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003;16:937-943.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
19. Skacel M, Skilton B, Pettay JD, et al. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immun Molecul Morphol. 2001;10:1-6.
20. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
21. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 2001;10:1331-1338.
22. Mengel M, Kreipe H, von Wasielewski R. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immun Molecul Morphol. 2003;11:261-268.
23. Bose S, Mohammed M, Shintaku P, et al. Her2-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J. 2001;7:337-344.
24. Jimenez RE, Wallis T, Tabasczka P, et al. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000;13:37-45.
25. Isola J, Chu L, DeVries S, et al. Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res. 1999;5:4140-4145.
26. Bukholm IRK, Bukholm G, Holm R, et al. Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol. 2003;56:368-373.